Ak. Lehmann et al., Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB, INFEC IMMUN, 67(5), 1999, pp. 2552-2560
Human opsonins directed against specific meningococcal outer membrane struc
tures in sera obtained during meningococcal disease were quantified with a
recently developed antigen-specific, opsonin-dependent phagocytosis and oxi
dative burst assay. Outer membrane vesicles (OMVs) and PorA (class 1) and P
orB (class 3) proteins purified from mutants of the same strain (44/76; B:1
5:P1.7.16) were adsorbed to fluorescent beads, opsonized with acute- and co
nvalescent-phase sera from 40 patients with meningococcal disease, and expo
sed to human leukocytes, Flow cytometric quantitation of the resulting leuk
ocyte phagocytosis products (PPs) demonstrated that disease induced serum o
psonins recognized meningococcal OMV components and both porins, The PPPorA
and PPPorB values induced by convalescent-phase sera correlated positively
with the PPOMV values. However, the PPPorB values were higher than the PPP
orA values In convalescent-phase sera (medians [ranges] of 754 [17 to 1,057
] and 107 [4 to 458], respectively) (P < 0.0001) and correlated positively
with higher levels of immunoglobulin G against PorB than against PorA as ev
aluated by enzyme linked immunosorbent assay. Extensive individual variatio
ns in the anti-OMV and antiporin serum opsonic activities between patients
infected by serotypes and serosubtypes homologous and heterologous to the t
arget antigens were observed. Simultaneously measured oxidative burst activ
ity correlated with the opsonophagocytosis, an indication that both of thes
e important steps in the in vitro phagocytic elimination of meningococci ar
e initiated by opsonins directed against OMV components, including PorA and
PorB, In conclusion, human patient opsonins against meningococcal OMV comp
onents and in particular PorB epitopes were Identified by this new method,
which might facilitate selection of opsonin-inducing meningococcal antigens
for inclusion in future vaccines.